A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an improved method for predicting treatment benefits in patients with hormone ...

BERLIN -- Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for patients with bone metastases from breast cancer, and also appeared to be ...

Breast cancers frequently spread to the bone, establishing tumors that are largely impervious to treatment and are associated with poor patient prognoses. A deficiency in the oxygen-carrying capacity ...

Researchers analyzed population-based data of 11,864 patients diagnosed with de novo metastatic cancer in 1976 and 26,324 patients diagnosed in 2015, with follow-up through 1981 and 2020.